Another study reported the benefits of curcumin (200 mg/kg) and epigallocatechin gallate (EGCG) (25 mg/kg) in lowering the tumour burden of xenograft models via the reduction in phosphorylated Akt, EGFR and vascular endothelial growth factor receptor-1 (VEGFR-1) expression, highlighting the enhanced anticancer potential of this treatment regimen [75]. The gene discussed is AKT1; the disease is neoplasm.